查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1864534

腦和脊髓癌市場：2025-2032年全球預測（按癌症類型、治療方法、患者年齡層、最終用戶和通路）

Brain & Spinal Cord Cancer Market by Cancer Type, Treatment Type, Patient Age Group, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，腦部和脊髓腫瘤治療市場將成長至 63.3 億美元，複合年成長率為 5.97%。

關鍵市場統計數據
基準年 2024 39.8億美元
預計年份：2025年 42.1億美元
預測年份 2032 63.3億美元
複合年成長率 (%) 5.97%

策略性地介紹臨床、監管和營運因素的融合如何重塑神經腫瘤學的診斷、治療和護理服務。

本執行摘要摘要了影響腦部和脊髓腫瘤治療的最重要臨床、運作和策略主題。分子特徵分析和精準醫學的進步正在重新定義診斷路徑，同時也為治療決策過程帶來了新的複雜性。不斷發展的醫療服務模式以及多學科協作日益重要的作用，也在改變患者對診斷、治療和復健的體驗。

監管路徑也同步發展，加速核准和適應性試驗設計使患者能夠更早獲得創新治療方法。這些創新伴隨著對真實世界證據和核准後數據日益成長的需求，相關人員必須將其納入生命週期規劃。同樣重要的是系統層面的因素，例如供應鏈脆弱性、人才短缺以及支付政策的爭議，這些因素都會影響創新成果的轉換應用。

總體而言，這些趨勢既為商業團隊、臨床領導者和支付方帶來了機會，也帶來了責任。本摘要系統地闡述了變革性轉變、關稅主導的供應考量、細分市場洞察、區域差異和競爭行為，旨在為神經腫瘤生態系統的策略和投資重點提供參考。

本書冷靜地檢驗了正在重塑神經腫瘤治療模式和相關人員期望的變革性科學、醫療服務和政策變化。

治療創新是推動改變的最主要動力，標靶治療藥物、免疫療法和先進的放射治療方法正在改變傳統的治療流程。精準診斷技術將患者按分子特徵分層，從而實現更個人化的治療計劃，同時也需要整合生物標記檢測基礎設施和新的診療路徑。這些科學進步與改進的手術流程和設備相輔相成，包括更安全的手術技術和高精度立體定位系統，這些共同降低了併發症的風險，並拓展了治療選擇的範圍。

醫療服務體係正經歷著一場同步的變革。多學科腫瘤諮詢、遠端醫療和分散式治療方案正在擴大醫療服務的覆蓋範圍，同時也對傳統的以醫院為中心的模式提出了挑戰。支付方和醫療系統正在探索基於價值的框架和按績效付費的合約模式，這些模式強調實際療效而非傳統的手術量。這些變革要求製造商和醫療服務提供者證明其產品具有持續的臨床效益，控制總醫療成本，並投資於長期實證醫學研究。

最後，患者的期望和訴求已成為塑造研究重點和監管討論的核心。患者要求治療方法不僅要延長生存期，還要保護神經功能和生活品質，因此，人們越來越關注神經認知終點和支持性護理的整合。由此，相關人員必須應對一個更複雜、以病人為中心的環境，這需要靈活應變、跨部門合作和強而有力的實證策略。

深入分析 2025 年美國關稅政策變化如何影響神經腫瘤治療方法和醫療設備的供應鏈、籌資策略和存取動態。

2025年美國關稅政策為腦癌和脊髓癌治療治療方法及醫療設備的採購、生產和整體全球籌資策略帶來了新的考量。活性藥物原料藥、醫療設備及相關耗材的關稅調整影響了成本結構，促使各企業重新評估供應商多元化和近岸外包方案。這些政策變化使企業更加關注最終落地成本，並獎勵企業建立本地製造夥伴關係和加強合約保護。

供應鏈中斷風險的增加凸顯了庫存可視性、多元化籌資策略以及關鍵物資（例如特效癌症治療藥物、植入式醫療設備和精準放射治療組件）策略儲備的重要性。製造商正透過重新設計物流網路、尋找替代供應商以及修訂定價合約來應對這一挑戰，以反映更高的進口成本和風險緩解投資。採購團隊和財務負責人比以往任何時候都更加積極主動地進行情境規劃，以量化關稅對營運的影響，並確保患者照護的連續性。

監管機構和商業部門也需要考慮價格上漲對醫療服務取得和報銷的潛在下游影響。支付者可能會透過調整藥品目錄策略和報銷率來應對採購成本的上漲，而醫療服務提供者則可能面臨利潤率壓力，這可能會影響新型高成本治療方法的推廣應用。因此，各機構應優先建立透明的供應商關係，倡導保護病患用藥的政策機制，並制定以證據為基礎的價值提案，使單價上漲與臨床和經濟效益相符。

高解析度分割分析揭示了腫瘤類型、治療方法、患者人口統計特徵、醫療機構和通路如何相互作用，從而決定臨床和商業性優先事項。

基於細分市場的分析揭示了腫瘤生物學、治療方法、年齡層、醫療環境和分銷管道等方面的細微需求模式和策略重點。按癌症類型分類的市場分析涵蓋星狀細胞瘤、室管膜瘤、膠質母細胞瘤、髓母細胞瘤、腦膜瘤、少突膠質瘤和神經鞘瘤，每種癌症都有其獨特的臨床病程、生物標記特徵和影響治療方案的手術考量。按治療方法分類，市場涵蓋化療、免疫療法、放射線治療、支持性治療、手術和分子標靶治療，其中化療進一步細分為烷化劑、亞硝基脲類藥物和含鉑類藥物。免疫療法細分為CAR-T細胞療法和查核點抑制劑；放射線治療細分為體外放射療法、質子療法和立體定位放射線手術；手術則分為開顱手術、雷射消熔和微創切除術。標靶治療的特點是使用激酶抑制劑和單株抗體。

患者的人口統計學特徵對臨床和商業性策略有顯著影響。基於患者年齡層的分析區分了成人、老年人和兒童群體，從而揭示了腫瘤生物學、耐受性和長期生存需求方面的差異。這些因素決定了不同的證據要求和服務模式。基於最終用戶，本研究檢視了門診手術中心、癌症診所、居家照護機構和醫院等不同醫療服務提供方式，反映了它們在實施複雜干預、處理併發症和協調多學科診療方面的不同能力。基於分銷管道，本研究評估了診所藥房、醫院藥房、線上藥房、零售藥房和專科藥房，並認知到通路選擇會影響用藥依從性、專科藥物的可及性和患者援助計劃。

整合這些細分觀點，可以凸顯組織應優先關注的交叉領域，例如：老年特定類型腫瘤患者的症狀如何影響積極手術和全身治療的適用性；兒童腫瘤生物學如何影響參與專科臨床試驗；放射治療方法如何取決於腫瘤位置和患者年齡；以及配銷通路策略如何促進或限制藥物依從性和居家支持護理計劃。這些見解有助於開發針對性產品、產生實證醫學證據並建立商業模式，以滿足神經腫瘤治療路徑的多樣化需求。

整合美洲、歐洲、中東和非洲以及亞太地區的臨床能力、監管複雜性和准入促進因素的區域情報，可協助您制定優先策略。

區域趨勢對腦部和脊髓腫瘤先進療法的可及性、臨床能力和法規環境有顯著影響。在美洲，綜合性學術中心和專科癌症網路推動了新型外科技術和先進放射治療方法的早期應用，而支付方的談判和報銷政策則決定了商業性推廣的速度。區域內的跨國合作有助於臨床試驗的招募和知識交流，但都市區三級醫療中心和社區醫療機構之間仍存在可近性差異，影響著複雜疾病治療的公平性。

儘管歐洲、中東和非洲地區（EMEA）已實現監管協調和區域採購機制，但各地區醫療系統能力仍有顯著差異。資源豐富的歐洲市場已發展出精準診斷和質子治療基礎設施，而中東和北非（MENA）地區的部分地區則專注於基礎設施建設、人才培養和擴大基本治療的可及性。因此，策略夥伴關係、技術轉移和能力建設舉措對於擴大這些市場的可近性至關重要。報銷框架和國家政策重點將影響先進治療方法的長期應用和永續性。

對腫瘤基礎設施的快速投資以及對國內生物技術創新日益重視，正在加速亞太地區標靶治療和先進放射治療服務的普及。然而，不同的支付系統和監管路徑造成了不同的市場准入考量。在許多地區，製造商必須應對複雜的當地報銷標準、價格談判以及公私合營，才能實現廣泛的市場准入。在不同地區，相關人員必須根據當地的監管要求、臨床實務規範和基礎設施實際情況，調整證據產生、市場進入策略和生產決策。

競爭考察重點在於神經腫瘤學市場領導的創新組合、策略夥伴關係和實證商業化方法。

主要企業正透過標靶治療、先進的放射治療平台和支持性護理解決方案等產品組合來脫穎而出。一些清晰的策略行為模式顯而易見：投資精準診斷以確保患者篩選的準確性；與學術機構合作以加速轉化研究和臨床試驗招募；以及透過授權許可擴大地域覆蓋範圍並降低研發風險。此外，他們也日益垂直整合特種化合物和無菌注射劑的供應鏈，以降低供應中斷的風險。

合作模式正從簡單的共同開發契約演變為包含資料共用框架、合作進行的真實世界證據研究以及按績效付費合約試點等多方面聯盟。這些安排使各機構能夠將報銷與已證實的患者獲益掛鉤，並共用臨床和財務風險。從商業角度來看，人們越來越關注患者支援服務、用於提高依從性的數位化互動工具以及中心輻射式分銷模式，以滿足複雜生物製藥和細胞療法的需求。

競爭優勢日益依賴展現長期神經系統療效和貫穿整個治療過程的價值，而非單一療效。因此，整合可靠的實證醫學證據、靈活的定價模式以及與醫療服務提供者網路建立策略合作夥伴關係的公司策略，將更有利於實現持續的市場認可，同時滿足支付方和患者的期望。

為產業領導者提供切實可行的優先建議，以加快治療效果、加強供應鏈並擴大神經腫瘤治療途徑中的公平獲取途徑。

產業領導者應採取一套平衡的短期和長期措施，以應對臨床影響、供應鏈韌性和公平取得等問題。優先投資生物標記項目和綜合診斷，以確保精準篩選患者並最大限度地提高治療效果。除了分子策略外，還應建立完善的註冊登記和真實世界證據項目，以收集神經認知結果和長期生活品質指標，這些指標在醫保報銷討論和臨床醫生採納治療方案方面發揮著日益重要的作用。

為降低關稅和進口風險，應透過多元化經營、尋找替代供應商以及考慮建立區域製造夥伴關係關係來加強供應鏈。在採購慣例中，建立合約彈性和庫存透明度至關重要，這有助於減輕政策變更帶來的營運負擔。在商業層面，應針對每個通路和醫療機構量身定做患者支援模式，確保在門診和居家醫療環境中適當整合專業護理、用藥依從性計劃和遠端監測。

最後，我們將建構一個涵蓋產業、醫療服務提供者和病患權益計劃團體的協作生態系統，以加速臨床試驗招募、統一證據優先順序並推動相關政策，從而保障商業性獲得高價值療法的機會。透過共同實施這些舉措，各組織可以將科學進步轉化為永續的臨床改善和永續成果。

我們採用透明、嚴謹的混合方法調查方法，結合文獻綜合、專家訪談和證據三角驗證，以支持我們的策略結論並承認其局限性。

本分析採用混合方法設計，結合系統性的二手資料研究和針對性的原始研究，以檢驗並填補證據空白。二手資料來源包括同儕審查文獻、臨床試驗註冊庫、監管文件和政策公告，全面展現了治療機制、臨床終點和監管先例。此文獻回顧優先考慮高品質的隨機對照試驗、關鍵醫療設備評估和共識指引更新，以最可靠的證據支持臨床解讀。

初步研究包括對臨床專家、醫療系統領導者、支付方代表和供應鏈專業人員的訪談，以收集他們對實施障礙、報銷趨勢和營運韌性的看法。專家見解被用於制定關稅影響、採購應對措施和區域產能限制的情境計畫。證據綜合分析採用主題編碼來協調相互衝突的觀點，並突顯策略行動的優先領域，而敏感度分析則揭示了各種依賴關係和潛在限制。

此調查方法的局限性包括監管決策的流動性以及臨床數據快速發展可能導致實踐模式發生變化。為彌補這些局限性，該調查方法在假設方面保持透明，明確指出關鍵輸入資料的獲取時間，並識別需要持續監測和定期更新的領域，以保持其策略相關性。

一項重要的綜合分析，重點強調了臨床創新、營運韌性和協調政策行動之間相互依存的優先事項，以改善神經腫瘤學的治療效果。

科學創新、醫療服務模式演變和政策轉變的交會動態，要求神經腫瘤學生態系統各部門協同應對。精準診斷和新型治療方法有望顯著提高患者存活率並保護神經功能，但要實現這一目標，需要強力的循證策略、穩健的供應鏈和公平的醫療資源獲取機制。因此，相關人員必須將臨床研發與真實世界證據的生成結合，儘早與支付方接洽，並以病人和醫療系統都能理解的方式清晰闡述其價值。

在營運層面，各機構應著重於供應鏈多元化、策略性製造夥伴關係關係以及能夠保障病患治療連續性的採購慣例，同時應對政策波動。針對不同地區的監管路徑、基礎設施和報銷模式，需要製定區域性策略。商業性成功將日益依賴整合式服務模式，將治療與診斷、病患支持服務和數位化工具結合，以提高病患依從性和治療效果。

摘要，要將進展轉化為持續改進，需要從系統層面觀點，平衡創新與實施。透過優先考慮證據生成、營運韌性和協作參與，相關人員可以加速顯著改善腦脊髓腫瘤患者的治療效果。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • CAR-T細胞療法在復發性多形性膠質母細胞瘤的應用日益廣泛，並提高了患者的存活率。
  • 將人工智慧驅動的放射組學和機器學習相結合，用於中樞神經系統癌症的精準診斷和治療計劃。
  • 開發聚焦超音波技術，以暫時破壞血腦障壁，從而實現膠質母細胞瘤的標靶藥物傳遞。
  • 增加對基於奈米顆粒的藥物遞送系統的投資，以增強脊椎腫瘤治療的標靶化
  • 增加腫瘤治療的使用可改善新診斷膠質母細胞瘤患者的無惡化生存期
  • 利用循環腫瘤DNA拓展液態生物檢體在腦轉移瘤早期檢測與後續觀察的應用
  • 針對IDH1突變的基因編輯方法在少突膠質細胞瘤和低度膠質瘤的治療研發中嶄露頭角
  • 生物技術公司與學術機構之間的合作正在不斷擴大，以開發用於治療中樞神經系統惡性腫瘤的新型免疫療法疫苗。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依癌症類型分類的腦部和脊髓癌市場

  • 星狀細胞瘤
  • 室管膜瘤
  • 膠質母細胞瘤
  • 髓母細胞瘤
  • 腦膜瘤
  • 少突膠質細胞
  • 神經鞘瘤

第9章 依治療方式分類的腦部和脊髓癌市場

  • 化療
    • 烷化劑
    • 亞硝基脲
    • 含鉑類藥物
  • 免疫療法
    • CAR-T細胞療法
    • 查核點抑制劑
  • 放射治療
    • 體外放射治療
    • 質子治療
    • 立體定位放射放射線手術
  • 支持性護理
  • 外科手術
    • 開顱手術
    • 雷射消熔
    • 微創切除術
  • 標靶治療
    • 激酶抑制劑
    • 單株抗體

第10章 依患者年齡層分類的腦部和脊髓癌市場

  • 成人版
  • 老年人
  • 孩子們

第11章 依最終用戶分類的腦部和脊髓癌市場

  • 門診手術中心
  • 癌症診所
  • 居家醫療環境
  • 醫院

第12章 腦和脊髓癌市場按通路分類

  • 診所藥房
  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專賣店

第13章 腦和脊髓癌市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 腦和脊髓癌市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國腦和脊髓癌市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Novartis AG
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • AstraZeneca PLC
    • AbbVie Inc.
    • Bayer AG
    • Novocure Limited
    • Eisai Co., Ltd.
Product Code: MRR-9E71DF483B96

The Brain & Spinal Cord Cancer Market is projected to grow by USD 6.33 billion at a CAGR of 5.97% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.98 billion
Estimated Year [2025] USD 4.21 billion
Forecast Year [2032] USD 6.33 billion
CAGR (%) 5.97%

A strategic introduction to the converging clinical, regulatory, and operational forces that are reshaping diagnosis, treatment, and care delivery in neuro-oncology

This executive summary distills the most consequential clinical, operational, and strategic themes shaping care for brain and spinal cord cancers. Advances in molecular characterization and precision therapeutics have redefined diagnostic pathways while concurrently introducing new complexity into treatment decision-making. At the same time, evolving care-delivery models and greater emphasis on multidisciplinary coordination are shifting how patients experience diagnosis, treatment, and survivorship.

Regulatory pathways are evolving in parallel, with accelerated approvals and adaptive trial designs enabling earlier patient access to novel interventions. These innovations come with heightened requirements for real-world evidence and post-approval data that stakeholders must integrate into lifecycle planning. Equally important are the system-level forces-supply chain fragility, workforce constraints, and payment policy debates-that influence how innovations translate into practice.

Taken together, these dynamics create both opportunity and responsibility for commercial teams, clinical leaders, and payers. This summary presents a structured view of the transformational shifts, tariff-driven supply considerations, segmentation-driven insights, regional distinctions, and competitive behaviors that should inform strategy and investment priorities across the neuro-oncology ecosystem.

A clear-eyed review of the transformative scientific, care-delivery, and policy shifts that are redefining neuro-oncology treatment paradigms and stakeholder expectations

Therapeutic innovation is the most visible driver of change, with targeted agents, immunotherapies, and advanced radiation modalities altering conventional treatment algorithms. Precision diagnostics now stratify patients into molecularly defined cohorts, enabling more personalized regimens but also requiring integrated biomarker testing infrastructure and new care pathways. These scientific advances are complemented by procedural and device improvements, including safer surgical techniques and more precise stereotactic delivery systems, which together reduce morbidity and expand treatment candidacy.

Care delivery is undergoing a parallel transformation. Multidisciplinary tumor boards, virtual care modalities, and decentralized treatment options are increasing access while challenging traditional hospital-centric models. Payers and health systems are experimenting with value-based frameworks and outcomes-based contracting, which emphasize real-world outcomes over traditional procedural volumes. These shifts force manufacturers and providers to demonstrate sustained clinical benefit, manage total cost of care, and invest in longitudinal evidence generation.

Finally, patient expectations and advocacy voices now play a central role in shaping research priorities and regulatory conversations. Patients seek therapies that not only extend survival but preserve neurologic function and quality of life, prompting greater attention to neurocognitive endpoints and supportive care integration. As a result, stakeholders must navigate a more complex, patient-centered landscape that demands agility, cross-sector partnerships, and robust evidence strategies.

An incisive assessment of how United States tariff policy changes in 2025 are reshaping supply chains, sourcing strategies, and access dynamics for neuro-oncology therapies and devices

United States tariff policies enacted in 2025 have introduced new considerations across procurement, manufacturing, and global sourcing strategies for therapies and devices used in brain and spinal cord cancer care. Tariff adjustments on active pharmaceutical ingredients, medical devices, and ancillary supplies affect cost structures and have prompted organizations to reassess supplier diversification and nearshoring options. These policy changes heightened attention to total landed cost and created incentives for local manufacturing partnerships and contractual protections.

Supply chain disruption risk has increased the premium on inventory visibility, multi-sourcing strategies, and strategic stockpiles for critical items such as specialty oncology drugs, implantable devices, and precision radiation components. Manufacturers are responding by redesigning logistics networks, qualifying alternate suppliers, and revising pricing contracts to reflect increased import costs and mitigation investments. Procurement teams and finance leaders are now more actively engaging in scenario planning to quantify tariff-related operational impacts and ensure continuity of patient care.

Regulatory and commercial teams must also account for potential downstream effects on access and reimbursement. Payers may adjust formulary strategies or reimbursement rates in response to higher acquisition costs, while providers could face pressure on margins that affects adoption of newer, higher-cost modalities. Therefore, organizations should prioritize transparent supplier relationships, advocate for policy mechanisms that protect patient access, and develop evidence-based value propositions that reconcile higher unit costs with clinical and economic outcomes.

High-resolution segmentation insights revealing how tumor types, therapeutic modalities, patient age cohorts, care settings, and distribution channels jointly determine clinical and commercial priorities

Segmentation-driven analysis reveals nuanced demand patterns and strategic priorities across tumor biology, therapeutic modality, age demographics, care settings, and distribution channels. Based on Cancer Type, market analysis covers Astrocytoma, Ependymoma, Glioblastoma, Medulloblastoma, Meningioma, Oligodendroglioma, and Schwannoma, each presenting distinct clinical courses, biomarker profiles, and surgical considerations that inform therapeutic choices. Based on Treatment Type, the landscape spans Chemotherapy, Immunotherapy, Radiation Therapy, Supportive Care, Surgery, and Targeted Therapy, with chemotherapy further detailed into Alkylating Agents, Nitrosoureas, and Platinum Based Agents; immunotherapy delineated into CAR T Cell Therapy and Checkpoint Inhibitors; radiation therapy separated into External Beam Radiation, Proton Therapy, and Stereotactic Radiosurgery; surgery differentiated by Craniotomy, Laser Ablation, and Minimally Invasive Resection; and targeted therapy characterized by Kinase Inhibitors and Monoclonal Antibodies.

Patient demographics materially influence clinical and commercial approaches. Based on Patient Age Group, the analysis distinguishes Adult, Geriatric, and Pediatric populations, capturing differences in tumor biology, tolerability, and long-term survivorship needs that drive distinct evidence requirements and service models. Based on End User, care delivery is examined across Ambulatory Surgical Centers, Cancer Clinics, Home Care Settings, and Hospitals, reflecting varied capabilities for delivering complex interventions, managing complications, and coordinating multidisciplinary care. Based on Distribution Channel, the study assesses Clinic Pharmacies, Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Specialty Stores, recognizing that channel choice affects adherence, specialty drug handling, and patient support programs.

Integrating these segmentation lenses highlights intersections that organizations must prioritize: for example, how geriatric presentations of specific tumor types alter suitability for aggressive surgery or systemic therapy; how pediatric tumor biology drives enrollment in specialized trials; how selection of radiation modality depends on tumor location and patient age; and how distribution channel strategies can either enable or constrain adherence and home-based supportive care programs. These insights support targeted product development, evidence generation, and commercial models that align with the heterogeneous needs across neuro-oncology care pathways.

Regional intelligence synthesizing clinical capacity, regulatory complexity, and access drivers across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform prioritized strategies

Regional dynamics materially influence clinical capacity, regulatory environments, and access to advanced therapies for brain and spinal cord cancers. In the Americas, integrated academic centers and specialized cancer networks often drive early adoption of novel surgical techniques and advanced radiation modalities, while payer negotiations and reimbursement policy shape the pace of commercial uptake. Cross-border collaboration within the region supports clinical trial enrollment and knowledge exchange, but disparities in access persist between urban tertiary centers and community providers, which affects equitable delivery of complex care.

In Europe, Middle East & Africa, regulatory harmonization and regional procurement mechanisms coexist with widely varying health system capacities. High-resource European markets exhibit strong capabilities for precision diagnostics and proton therapy infrastructure, whereas parts of the Middle East and Africa emphasize capacity building, workforce development, and access to essential therapies. Strategic partnerships, technology transfer, and capacity-strengthening initiatives are therefore central to expanding access in these markets. Reimbursement frameworks and national policy priorities influence long-term adoption and the sustainability of advanced modalities.

In the Asia-Pacific region, rapid investments in oncology infrastructure and a growing emphasis on domestic biotech innovation are accelerating availability of targeted agents and advanced radiation services. However, heterogeneous payer systems and regulatory pathways create varying commercial entry considerations. In many jurisdictions, manufacturers must navigate complex local reimbursement criteria, pricing negotiations, and public-private partnerships to achieve broad access. Across regions, stakeholders should tailor evidence generation, access strategies, and manufacturing decisions to reflect local regulatory expectations, clinical practice norms, and infrastructure realities.

Competitive company insights emphasizing innovation portfolios, strategic partnerships, and evidence-driven commercialization approaches that differentiate market leaders in neuro-oncology

Leading companies in the neuro-oncology space are differentiating through integrated portfolios that combine targeted agents, advanced radiation platforms, and supportive care solutions. Strategic behaviors fall into several observable patterns: investment in precision diagnostics to ensure appropriate patient selection; partnerships with academic centers to accelerate translational research and trial enrollment; and licensing agreements that expand geographic reach while mitigating development risk. Firms are also pursuing vertical integration in supply chains for specialty compounds and sterile injectable formulations to reduce disruption risk.

Collaboration models are evolving from simple co-development agreements to multifaceted alliances that include data-sharing frameworks, joint real-world evidence initiatives, and outcomes-based contracting pilots. These arrangements allow organizations to align reimbursement with demonstrated patient benefit and to share both clinical and financial risk. From a commercialization perspective, companies are placing greater emphasis on patient support services, digital engagement tools to improve adherence, and hub-and-spoke distribution models that accommodate the handling needs of complex biologics and cell therapies.

Competitive differentiation increasingly depends on demonstrating long-term neurologic outcomes and value across care episodes rather than single-point efficacy. As a result, corporate strategies that integrate robust evidence generation, adaptive pricing models, and strategic partnerships with provider networks will be better positioned to capture sustained uptake while addressing payer and patient expectations.

Practical and prioritized recommendations for industry leaders to accelerate therapeutic impact, fortify supply chains, and expand equitable access within neuro-oncology care pathways

Industry leaders should pursue a balanced set of near-term and long-term actions that address clinical impact, supply chain resilience, and equitable access. Prioritize investment in biomarker programs and integrated diagnostics to ensure precise patient selection and to maximize therapeutic benefit. Complement molecular strategies with robust registries and real-world evidence programs that capture neurocognitive outcomes and longitudinal quality-of-life measures, which are increasingly central to reimbursement discussions and clinician adoption.

Strengthen supply chains through diversification, qualification of alternate suppliers, and consideration of regional manufacturing partnerships to mitigate tariff and import risks. Build contractual flexibility and inventory visibility into procurement practices to reduce the operational strain of policy shifts. On the commercial front, design patient support models that align with distinct distribution channels and care settings, ensuring that specialty handling, adherence programs, and remote monitoring are embedded within the ambulatory and home-care contexts where appropriate.

Finally, cultivate collaborative ecosystems across industry, providers, and patient advocacy groups to accelerate trial enrollment, align evidence priorities, and advocate for policies that preserve access to high-value interventions. Implementing these steps in concert will enable organizations to convert scientific advances into durable clinical improvements and sustainable commercial outcomes.

A transparent and rigorous mixed-methods research approach that combines literature synthesis, expert interviews, and evidence triangulation to underpin strategic conclusions and acknowledge limitations

The analysis integrates a mixed-methods research design that pairs systematic secondary research with targeted primary engagements to validate findings and fill evidence gaps. Secondary sources included peer-reviewed literature, clinical trial registries, regulatory documents, and policy releases to construct a comprehensive view of therapeutic mechanisms, clinical endpoints, and regulatory precedents. This literature synthesis prioritized high-quality randomized trials, pivotal device evaluations, and consensus guideline updates to ground clinical interpretations in the strongest available evidence.

Primary research comprised interviews with clinical experts, health system leaders, payer representatives, and supply chain professionals to elicit perspectives on adoption barriers, reimbursement dynamics, and operational resilience. Expert input informed scenario planning around tariff impacts, procurement responses, and regional capacity constraints. Evidence synthesis applied thematic coding to reconcile divergent viewpoints and to surface priority areas for strategic action, while sensitivity assessments highlighted dependencies and potential limitations.

Limitations of the methodology include the evolving nature of regulatory decisions and rapidly emerging clinical data that may alter practice patterns. To mitigate these constraints, the study emphasizes transparent assumptions, documents data vintage for key inputs, and identifies areas where ongoing surveillance and periodic updates will be necessary to maintain strategic relevance.

A conclusive synthesis that emphasizes the interdependent priorities of clinical innovation, operational resilience, and collaborative policy action necessary to improve neuro-oncology outcomes

The convergent forces of scientific innovation, evolving care delivery, and shifting policy require coordinated responses across the neuro-oncology ecosystem. Precision diagnostics and novel therapeutics offer genuine promise for improving survival and preserving neurologic function, yet realizing that promise depends on robust evidence strategies, resilient supply chains, and equitable access frameworks. Stakeholders must therefore align clinical development with real-world evidence generation and engage payers early to articulate value in terms that matter to patients and health systems.

Operationally, organizations should focus on supply chain diversification, strategic manufacturing partnerships, and procurement practices that absorb policy shocks while protecting patient continuity of care. Region-specific strategies will be necessary to reflect heterogeneity in regulatory pathways, infrastructure, and reimbursement models. Commercial success will increasingly hinge on integrated offers that combine therapeutics with diagnostics, patient support services, and digital tools that facilitate adherence and outcome measurement.

In summary, transforming advances into durable improvements requires a systems-level perspective that balances innovation with practical implementation. By prioritizing evidence generation, operational resilience, and collaborative engagement, stakeholders can accelerate meaningful improvements in outcomes for people affected by brain and spinal cord cancers.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of CAR T-cell therapies for recurrent glioblastoma multiforme improving survival outcomes
  • 5.2. Integration of AI-driven radiomics and machine learning for precision diagnosis and treatment planning in CNS cancers
  • 5.3. Development of focused ultrasound techniques to transiently disrupt the blood-brain barrier for targeted drug delivery in gliomas
  • 5.4. Increasing investment in nanoparticle-based drug delivery systems for spinal cord tumor therapeutics with enhanced targeting
  • 5.5. Expansion of tumor treating fields therapy utilization in newly diagnosed glioblastoma patients to extend progression free survival
  • 5.6. Rise of liquid biopsy applications using circulating tumor DNA for early detection and monitoring of brain metastases
  • 5.7. Emergence of gene editing approaches targeting IDH1 mutations in oligodendroglioma and low-grade glioma treatment pipelines
  • 5.8. Growing collaboration between biotech firms and academic centers for novel immunotherapeutic vaccine development in CNS malignancies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain & Spinal Cord Cancer Market, by Cancer Type

  • 8.1. Astrocytoma
  • 8.2. Ependymoma
  • 8.3. Glioblastoma
  • 8.4. Medulloblastoma
  • 8.5. Meningioma
  • 8.6. Oligodendroglioma
  • 8.7. Schwannoma

9. Brain & Spinal Cord Cancer Market, by Treatment Type

  • 9.1. Chemotherapy
    • 9.1.1. Alkylating Agents
    • 9.1.2. Nitrosoureas
    • 9.1.3. Platinum Based Agents
  • 9.2. Immunotherapy
    • 9.2.1. CAR T Cell Therapy
    • 9.2.2. Checkpoint Inhibitors
  • 9.3. Radiation Therapy
    • 9.3.1. External Beam Radiation
    • 9.3.2. Proton Therapy
    • 9.3.3. Stereotactic Radiosurgery
  • 9.4. Supportive Care
  • 9.5. Surgery
    • 9.5.1. Craniotomy
    • 9.5.2. Laser Ablation
    • 9.5.3. Minimally Invasive Resection
  • 9.6. Targeted Therapy
    • 9.6.1. Kinase Inhibitors
    • 9.6.2. Monoclonal Antibodies

10. Brain & Spinal Cord Cancer Market, by Patient Age Group

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Brain & Spinal Cord Cancer Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Cancer Clinics
  • 11.3. Home Care Settings
  • 11.4. Hospitals

12. Brain & Spinal Cord Cancer Market, by Distribution Channel

  • 12.1. Clinic Pharmacies
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies
  • 12.5. Specialty Stores

13. Brain & Spinal Cord Cancer Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Brain & Spinal Cord Cancer Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Brain & Spinal Cord Cancer Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Novartis AG
    • 16.3.2. F. Hoffmann-La Roche Ltd
    • 16.3.3. Pfizer Inc.
    • 16.3.4. Merck & Co., Inc.
    • 16.3.5. Bristol-Myers Squibb Company
    • 16.3.6. AstraZeneca PLC
    • 16.3.7. AbbVie Inc.
    • 16.3.8. Bayer AG
    • 16.3.9. Novocure Limited
    • 16.3.10. Eisai Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRAIN & SPINAL CORD CANCER MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BRAIN & SPINAL CORD CANCER MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BRAIN & SPINAL CORD CANCER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EPENDYMOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EPENDYMOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EPENDYMOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EPENDYMOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EPENDYMOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EPENDYMOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MEDULLOBLASTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MEDULLOBLASTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MEDULLOBLASTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MEDULLOBLASTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MEDULLOBLASTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MEDULLOBLASTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY OLIGODENDROGLIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY OLIGODENDROGLIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY OLIGODENDROGLIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY OLIGODENDROGLIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SCHWANNOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SCHWANNOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SCHWANNOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SCHWANNOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SCHWANNOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SCHWANNOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NITROSOUREAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NITROSOUREAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NITROSOUREAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NITROSOUREAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NITROSOUREAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NITROSOUREAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PROTON THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PROTON THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PROTON THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PROTON THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PROTON THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PROTON THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CRANIOTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CRANIOTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CRANIOTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CRANIOTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CRANIOTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CRANIOTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY LASER ABLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY LASER ABLATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY LASER ABLATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY LASER ABLATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY LASER ABLATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY LASER ABLATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MINIMALLY INVASIVE RESECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MINIMALLY INVASIVE RESECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MINIMALLY INVASIVE RESECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MINIMALLY INVASIVE RESECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MINIMALLY INVASIVE RESECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MINIMALLY INVASIVE RESECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CLINIC PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CLINIC PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CLINIC PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CLINIC PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CLINIC PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CLINIC PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SPECIALTY STORES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SPECIALTY STORES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SPECIALTY STORES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SPECIALTY STORES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SPECIALTY STORES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SPECIALTY STORES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA BRAIN & SPINAL CORD CANCER MARKET SI